All In Biotech

Drug Trial Radar · NCT06387342

Namodenoson Treatment of Advanced Pancreatic Cancer

CF102-222PC: A Phase 2 Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Nov 10, 2024

Primary completion

Jul 15, 2026

Study completion Dec 15, 2026

Sponsor

Lead sponsor
Can-Fite BioPharmaIndustry
Sponsor type
Industry
First posted
Apr 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.

Conditions

  • Pancreatic Adenocarcinoma
  • Pancreatic Cancer

Interventions

  • Namodenoson 25mgDrug

    oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: Every 2 weeks, assessed up to 1 year
  2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Change from baselineTime frame: Every 2 weeks, assessed up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rabin Medical Center Institute of Oncology

    Petah Tikva, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.